Vildagliptin – 50 mg

Brand:
Cayman
CAS:
274901-16-5
Storage:
-20
UN-No:
Non-Hazardous - /

Glyptins are a class of oral antihyperglycemic agents that inhibit dipeptidyl peptidase 4 (DPP-4), which can act as a serine exopeptidase.{24375} In addition to having use in type 2 diabetes, gliptins have positive cardiovascular and anti-inflammatory effects.{24375,17148,24374} Vildagliptin is an inhibitor of DPP-4 (IC50 = 3.5-34 nM).{24373,24372} It also inhibits DPP-8 and DPP-9 (Ki = 810 and 95 nM, respectively) but not DPP-2 or the related fibroblast activation protein α.{24377} Through its effects on DPP-4, it blocks the degradation of several circulating peptides, including incretins (stimulators of insulin secretion) like glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1.{24376,24378} Vildagliptin reduces fasting and postprandial glucose levels and decreases inflammatory and oxidative stress in diverse animal models of disease.{24375,24374}  

 

SKU: - Category:

Description

An inhibitor of DPP-4 (IC50 = 3.5-34 nM); also inhibits DPP-8 and DPP-9 (Ki = 810 and 95 nM, respectively) but not DPP-2 or FAPα; blocks the degradation of several circulating peptides, including incretins; reduces fasting and postprandial glucose levels and decreases inflammatory and oxidative stress


Formal name: 1-[2-[(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)amino]acetyl]-2S-pyrrolidinecarbonitrile

Synonyms: 

Molecular weight: 303.4

CAS: 274901-16-5

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Small Molecule Inhibitors|MMPs||Product Type|Biochemicals|Small Molecule Inhibitors|Peptidases & Proteases||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Diabetes||Research Area|Immunology & Inflammation